Manhattan Biosolutions

Executive Summary

Manhattan BioSolutions (MBS) is a private biotechnology company developing next-generation antibody-drug conjugates (ADCs) inspired by evolutionary mechanisms. Their platform aims to improve tumor targeting and payload release, leveraging multiple immune-mediated and direct anti-tumor mechanisms to selectively eliminate cancer cells. Founded in 2018 and headquartered in New York, the company is currently at Phase 1 stage, indicating their lead candidate has entered initial clinical testing. While specific financial details and pipeline information are undisclosed, MBS's focus on differentiated ADC design positions it within a rapidly growing oncology market, with ADCs expected to exceed $20 billion in sales by 2028. The company's evolution-inspired approach could address key limitations of earlier ADCs, such as off-target toxicity and suboptimal payload delivery. MBS's early-stage status implies significant risk but also substantial upside potential if clinical data prove favorable. The company's success hinges on generating compelling safety and efficacy results from ongoing or planned Phase 1 trials, securing additional funding to advance its pipeline, and potentially forming strategic partnerships with larger pharmaceutical firms. Given the competitive ADC landscape, MBS must demonstrate clear differentiation and robust preclinical/clinical profiles. Conviction is moderate, reflecting early development stage and limited public information.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 safety and efficacy data readout for lead ADC candidate40% success
• H1 2027Series B or later-stage financing round to extend runway55% success
• 2027Potential partnership or licensing deal with a large pharma for co-development30% success